Optimal left ventricular ejection fraction in risk stratification of patients with cardiac sarcoidosis
Europace · 02.08.2023 · 25 (9)
DOI: 10.1093/europace/euad273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, online erschienen am 18.09.2023. Verfasst von Erika Hutt und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH 44195, USA. Hauptthemen laut MEDLINE: Sarcoidosis, Myocarditis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Identifying patients with cardiac sarcoidosis (CS) who are at an increased risk of sudden cardiac death (SCD) poses a clinical challenge. We sought to identify the optimal cutoff for left ventricular ejection fraction (LVEF) in predicting ventricular arrhythmia (VA) and all-cause mortality and to identify clinical and imaging risk factors in patients with known CS. Methods and results This retrospective cohort included 273 patients with well-established CS. The primary endpoint was a composite of VA and all-cause mortality. A modified receiver operating curve analysis was utilized to identify the optimal cutoff for LVEF in predicting the primary composite endpoint. Cox proportional hazard regression analysis was used to identify independent risk factors of the outcomes. At median follow-up of 7.9 years, the rate of the primary endpoint was 38% (83 VAs and 32 all-cause deaths). The 5-year overall survival rate was 97%. The optimal cutoff LVEF for the primary composite endpoint was 42% in the entire cohort and in subjects without a history of VA. Younger age, history of VA, lower LVEF, and any presence of scar by cardiac magnetic resonance (CMR) imaging and/or positron emission tomography (PET) were found to be independent risk factors for the primary endpoint and for VA, whereas lower LVEF, baseline NT-proBNP, and any presence of scar were independent risk factor of all-cause mortality.
Conclusion
Among patients with CS, a mild reduction in LVEF of 42% was identified as the optimal cutoff for predicting VA and all-cause mortality. Prior VA and scar by CMR or PET are strong risk factors for future VA and all-cause mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH 44195, USA.
- Department of Internal Medicine, Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Section of Cardiac Electrophysiology and Pacing, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Section of Heart Failure and Transplantation Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Sarcoidosis Center, Respiratory Institute Cleveland Clinic, Cleveland, OH 44195, USA.
ORCID-Profile: Erika Hutt, Maria Vega Brizneda, Jose Aguilera, Tom Kai Ming Wang, Thomas Callahan, W H Wilson Tang, Paul C Cremer, Wael A Jaber, Christine L Jellis
Zitieren
APA
Hutt, E., Brizneda, M. V., Goldar, G., Aguilera, J., Wang, T. K. M., Taimeh, Z., Culver, D., Callahan, T., Tang, W. H. W., Cremer, P. C., Jaber, W. A., Ribeiro Neto, M. L., & Jellis, C. L. (2023). Optimal left ventricular ejection fraction in risk stratification of patients with cardiac sarcoidosis. Europace, 25(9). https://doi.org/10.1093/europace/euad273
Vancouver
Hutt E, Brizneda MV, Goldar G, Aguilera J, Wang TKM, Taimeh Z, et al. Optimal left ventricular ejection fraction in risk stratification of patients with cardiac sarcoidosis. Europace. 2023;25(9). doi:10.1093/europace/euad273
BibTeX
@article{Hutt2023,
author = {Hutt, Erika and Brizneda, Maria Vega and Goldar, Ghazaleh and Aguilera, Jose and Wang, Tom Kai Ming and Taimeh, Ziad and Culver, Daniel and Callahan, Thomas and Tang, W H Wilson and Cremer, Paul C and Jaber, Wael A and Ribeiro Neto, Manuel L and Jellis, Christine L},
title = {Optimal left ventricular ejection fraction in risk stratification of patients with cardiac sarcoidosis},
journal = {Europace},
year = {2023},
volume = {25},
number = {9},
doi = {10.1093/europace/euad273}
}
EUVIMED